EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

• Stifel 2026 Virtual Ophthalmology Forum
  Forum: Fireside Chat
  Date: May 26, 2026
  Time: 9:00 am ET
  

• Jefferies Global Healthcare Conference
  Forum: Fireside Chat
  Date: June 3, 2026
  Time: 4:55 p.m. ET
  
• Goldman Sachs 47th Annual Global Healthcare Conference
  Forum: Fireside Chat
  Date: June 9, 2026
  Time: 11:20 a.m. ET

A webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
[email protected] / [email protected]

Media:

Helen O’Gorman
FTI Consulting
[email protected]

Source: EyePoint, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SEACOR Marine Acknowledges Receipt of Letter by Shareholder
• FTI Consulting Strengthens Risk, Compliance & AI Advisory Capabilities in Australia With Appointment of Jerome Nyssen
• Suburban Water Systems Invests $10.9 Million in La Puente Water Treatment Plant